ストックスクリーナーアプリを入手
6.62
2.22%
-0.15
前日終値:
$6.77
開ける：
$6.84
24時間の取引高:
109.33K
Relative Volume:
0.41
時価総額：
$40.97M
収益：
$4.71M
当期純損益:
$-90.32M
株価収益率:
-0.7606
EPS:
-8.7032
ネットキャッシュフロー:
$-85.19M
1週間 パフォーマンス:
+18.43%
1か月 パフォーマンス:
+28.29%
6か月 パフォーマンス:
-26.44%
1年 パフォーマンス:
-24.69%
1日の値動き範囲:
$6.34
$6.85
1週間の範囲:
$5.44
$7.08
52週間の値動き範囲:
$4.80
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
名前
Aligos Therapeutics Inc
セクター
電話
(800) 466-6059
住所
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
6.62 | 40.97M | 4.71M | -90.32M | -85.19M | -8.7032 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-19 | 再開されました | Jefferies | Buy |
| 2025-08-18 | 再開されました | H.C. Wainwright | Buy |
| 2024-08-19 | 開始されました | H.C. Wainwright | Buy |
| 2023-01-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-01-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-09 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 再開されました | Piper Sandler | Overweight |
| 2020-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 開始されました | JP Morgan | Overweight |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Aligos Therapeutics Inc (ALGS) 最新ニュース
ALGS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
ALGS stock rallies 16% after-hours on $25M cash boost from China hepatitis B drug deal - MSN
H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy - Investing.com
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
Aligos commences dosing in Phase II trial for chronic hepatitis B treatment - MSN
Aligos Therapeutics stock is trending overnight: Here's what's going on with ALGS stock - MSN
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Aligos Therapeutics Secures $25M Upfront Payment in Licensing De - GuruFocus
Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock - Benzinga
Aligos receives $25M upfront payment from China licensing deal - Investing.com UK
Aligos Therapeutics' Shares Rally Following $25M Payment From Xiamen Amoytop Biotech - Moomoo
Aligos Therapeutics stock jumps on $25M China licensing deal By Investing.com - Investing.com South Africa
Why is Aligos Therapeutics stock surging today? By Investing.com - Investing.com Canada
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - Investing News Network
Aligos receives $25M upfront payment from China licensing deal By Investing.com - Investing.com Nigeria
Aligos Therapeutics stock jumps on $25M China licensing deal - Investing.com
China grants breakthrough status to Aligos’ HBV drug after $25M deal - Stock Titan
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill
Discipline and Rules-Based Execution in ALGS Response - Stock Traders Daily
Form 4 Aligos Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
Form 4 Aligos Therapeutics Inc For: 29 June - Investing.com India
Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 - Stock Titan
Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 strike - Stock Titan
Aligos Therapeutics (ALGS) director granted 5,860 options at $5.50 strike - Stock Titan
Director at Aligos (ALGS) granted option on 5,860 common shares - Stock Titan
Aligos Therapeutics (ALGS) director gets 5,860-share stock option grant - Stock Titan
Aligos Therapeutics (ALGS) director receives stock options for 5,860 shares at $5.50 - Stock Titan
Aligos Therapeutics, Inc.(NasdaqCM:ALGS) added to Russell Microcap Value Benchmark Index - marketscreener.com
Aligos Therapeutics, Inc.(NasdaqCM: ALGS) added to Russell 3000E Index - marketscreener.com
Aligos Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALGS) - TradingView
Aligos Therapeutics, Inc.(NasdaqCM: ALGS) added to Russell Microcap Index - marketscreener.com
Aligos Therapeutics, Inc.(NasdaqCM: ALGS) added to Russell 3000E Value Benchmark - marketscreener.com
Aligos Therapeutics Shareholders Approve Directors and Governance Changes - TipRanks
Aligos Therapeutics (ALGS) shareholders approve ESPP changes and annual say-on-pay - Stock Titan
ALGS Forecast — Price Target — Prediction for 2027 - TradingView
5WK0 Forecast — Price Target — Prediction for 2027 - TradingView
Aligos Therapeutics, Inc. Actuals & Estimates (DUS:5WK0) - TradingView
Price to sales forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Enterprise value to EBIT forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Enterprise value to revenue forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Enterprise value to EBITDA forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Price to book forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Price to earnings forward of Aligos Therapeutics, Inc. – NASDAQ:ALGS - TradingView
Lawrence M. Blatt Discloses Investment at Aligos Therapeutics with 5.6% Stake - TradingView
Aligos Therapeutics (NASDAQ: ALGS) CEO discloses 5.6% stake in Schedule 13D filing - Stock Titan
Aligos Therapeutics Inc (ALGS) Institutional Confidence - TradingKey
Aligos Therapeutics Inc (ALGS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Behavioral Patterns of ALGS and Institutional Flows - Stock Traders Daily
Aligos Therapeutics Inc (ALGS) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):